The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

NCT02006888 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

394

Enrollment

INDUSTRY

Sponsor class

Conditions

Inflammation
Cataracts

Interventions

DRUG: IBI-10090
DRUG: Placebo

Sponsor

ICON Bioscience Inc